FAQs about Bafiertam
Bafiertam received its final approval from the U.S. Food and Drug Administration in April 2020 for use in adults with relapsing forms of multiple sclerosis. It is indicated for clinically isolated syndrome, relapsing-remitting multiple sclerosis, and secondary progressive multiple sclerosis.
Animal studies suggest that Bafiertam may cause harm to a developing fetus. Patients who become or expect to become pregnant while on the medication should discuss their plans with a healthcare provider.
There are no alcohol or dietary restrictions for the medication, according to Banner Life Sciences, the company that developed Bafiertam. Nevertheless, people with a history of alcoholism have been excluded from clinical trials testing the therapy. Also, notably, patients taking Tecfidera and Vumerity, which are similar MS treatments, are advised not to drink alcohol at the same time as they take the medication. Since alcohol and Bafiertam can both cause can damage to the liver, patients should discuss with their healthcare provider whether it is safe to drink alcohol while on the therapy.
Because each patient will have a different disease experience, each person’s treatment response also will be unique. Patients are advised to speak with their healthcare providers about how Bafiertam may help in their case.
Weight gain and hair loss were not reported as side effects of Bafiertam in clinical trials. Some people who received Tecfidera, a medication with the same active ingredient, reported experiencing hair loss when using the treatment after its approval. Patients who experience these or other unexpected side effects should discuss them with their healthcare team.